Cargando…
COVID-19 associated mold infections: Review of COVID-19 associated pulmonary aspergillosis and mucormycosis
COVID-19-associated mold infection (CAMI) is defined as development of mold infections in COVID-19 patients. Co-pathogenesis of viral and fungal infections include the disruption of tissue barrier following SARS CoV-2 infection with the damage in the alveolar space, respiratory epithelium and endoth...
Autores principales: | Huang, Shiang-Fen, Ying-Jung Wu, Alice, Shin-Jung Lee, Susan, Huang, Yu-Shan, Lee, Chun-Yuan, Yang, Te-Liang, Wang, Hsiao-Wei, Chen, Hung Jui, Chen, Yi Ching, Ho, Tzong-Shiann, Kuo, Chien-Feng, Lin, Yi-Tsung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751001/ https://www.ncbi.nlm.nih.gov/pubmed/36586744 http://dx.doi.org/10.1016/j.jmii.2022.12.004 |
Ejemplares similares
-
COVID-19 associated with concomitant mucormycosis and aspergillosis
por: Lai, Chih-Cheng, et al.
Publicado: (2022) -
COVID-19-associated mixed mold infection: A case report of aspergillosis and mucormycosis and a literature review
por: Benhadid-Brahmi, Yasmine, et al.
Publicado: (2022) -
Recommendations and guidelines for the diagnosis and management of Coronavirus Disease-19 (COVID-19) associated bacterial and fungal infections in Taiwan
por: Wu, Huan-Yi, et al.
Publicado: (2023) -
Pulmonary aspergillosis and mucormycosis in a patient with COVID-19
por: Johnson, Andre K., et al.
Publicado: (2021) -
Immunosuppressants/Antifungals: COVID-19 associated mucormycosis, COVID-19 associated pulmonary aspergillosis and lack of efficacy: case report
Publicado: (2022)